Daratumumab: A Review in Relapsed and/or Refractory Multiple Myeloma.

about

A historical perspective on milestones in multiple myeloma research.

P2860

Q48196787-48341696-1625-4DC3-B0F8-BBB26B911EFF

P2860

Daratumumab: A Review in Relapsed and/or Refractory Multiple Myeloma.

Item

http://www.wikidata.org/entity/Q47614728

description

2017 nî lūn-bûn

@nan

2017年の論文

@ja

2017年学术文章

@wuu

2017年学术文章

@zh-cn

2017年学术文章

@zh-hans

2017年学术文章

@zh-my

2017年学术文章

@zh-sg

2017年學術文章

@yue

2017年學術文章

@zh

2017年學術文章

@zh-hant

name

Daratumumab: A Review in Relapsed and/or Refractory Multiple Myeloma.

@en

Daratumumab: A Review in Relapsed and/or Refractory Multiple Myeloma.

@nl

type

Item

label

Daratumumab: A Review in Relapsed and/or Refractory Multiple Myeloma.

@en

Daratumumab: A Review in Relapsed and/or Refractory Multiple Myeloma.

@nl

prefLabel

Daratumumab: A Review in Relapsed and/or Refractory Multiple Myeloma.

@en

Daratumumab: A Review in Relapsed and/or Refractory Multiple Myeloma.

@nl

P1476

Daratumumab: A Review in Relapsed and/or Refractory Multiple Myeloma.

@en

P2093

Hannah A Blair

http://www.w3.org/2001/XMLSchema#string

P2860

Monoclonal antibodies in the treatment of multiple myeloma: current status and future perspectives

Targeting CD38 with Daratumumab Monotherapy in Multiple Myeloma

Analysis of Real-World Data on Overall Survival in Multiple Myeloma Patients With ≥3 Prior Lines of Therapy Including a Proteasome Inhibitor (PI) and an Immunomodulatory Drug (IMiD), or Double Refractory to a PI and an IMiD.

Phase 1/2 study of daratumumab, lenalidomide, and dexamethasone for relapsed multiple myeloma.

Daratumumab, Bortezomib, and Dexamethasone for Multiple Myeloma.

Daratumumab, Lenalidomide, and Dexamethasone for Multiple Myeloma.

Risk of progression and survival in multiple myeloma relapsing after therapy with IMiDs and bortezomib: a multicenter international myeloma working group study.

Daratumumab, a novel therapeutic human CD38 monoclonal antibody, induces killing of multiple myeloma and other hematological tumors.

Resolving the daratumumab interference with blood compatibility testing.

Antibody-mediated phagocytosis contributes to the anti-tumor activity of the therapeutic antibody daratumumab in lymphoma and multiple myeloma

P2888

s40265-017-0837-7

P304

2013-2024

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1007/S40265-017-0837-7

http://www.w3.org/2001/XMLSchema#string

P433

http://www.w3.org/2001/XMLSchema#string

P478

http://www.w3.org/2001/XMLSchema#string

P577

2017-11-10T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P698

29127588

http://www.w3.org/2001/XMLSchema#string

Daratumumab: A Review in Relapsed and/or Refractory Multiple Myeloma.

about

P2860

P2860

Daratumumab: A Review in Relapsed and/or Refractory Multiple Myeloma.

description

name

type

label

prefLabel

P1433

P1476

P2093

P2860

P2888

P304

P31

P356

P433

P478

P577

P698

P356

P1433

P1476

P2093

P2860

P2888

P304

P31

P356

P433

P478

P577

P698